Lung cancer circulating tumour DNA study pathology data
Research type
Research Study
Full title
Lung cancer circulating tumour DNA study pathology data
IRAS ID
329708
Contact name
Nitzan Rosenfeld
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
The Lung Cancer Circulating Tumour DNA study (Lucid) REC 14/WM/1072 was initially published:
Gale D, Heider K, Ruiz-Valdepenas A,....Rintoul RC, Rosenfeld N. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol. 2022 May;33(5):500-510. doi: 10.1016/j.annonc.2022.02.007. Epub 2022 Mar 17. PMID: 35306155; PMCID: PMC9067454.This work has been well received and has already been cited by other groups 45 times.
The Lucid study has now closed but we would like to go back and collect some further data from the existing NHS surgical resection pathology reports. The reason for this is that another research group based in the Netherlands has done some similar work and they have approached us about combining our data sets for a joint publication. However to do this effectively we need to bring the two datasets into line with one another. We have been asked if we can collect some additional pathology data.
The data we would like to collect from the existing pathology reports are:
The stage of differentiation of the lung cancer
The histological sub-type of cases of adenocarcinoma
The lymphatic involvement status of the cancer
The final pathology TNM status
The diameter (in mm) of the resected cancer.REC name
London - Riverside Research Ethics Committee
REC reference
23/PR/1068
Date of REC Opinion
29 Sep 2023
REC opinion
Favourable Opinion